Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03504241 · ClinicalTrials.gov registry record · Phase 1
Tolerance by Engaging Antigen During Cellular Homeostasis
A Phase 1 study of Kidney Transplantation and Renal Transplantation, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT03504241 is a Phase 1 study of Kidney Transplantation and Renal Transplantation that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 8 participants, below the 268-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03504241, a Phase 1 study of Kidney Transplantation and Renal Transplantation, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
Anti-rejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent rejection of the new organ. Long-term use of these medicines places transplant recipients at higher risk of serious infections and certain types of cancer. The purpose of this study is to determine if: * it is safe to give mesenchymal stromal cells (MSCs) to kidney transplant recipients, and * the combination of the immunosuppressive (anti-rejection) study drugs plus the MSCs can allow a kidney transplant recipient to slowly reduce and/or then completely stop all anti-rejection drugs, without rejection of their kidney (renal) allograft, a process called "immunosuppression withdrawal".
Conditions Studied
Interventions
- DRUG sirolimus
- DRUG mycophenolate mofetil
- BIOLOGICAL Donor-derived Mesenchymal Stromal Cells
- DRUG alemtuzumab
- DRUG belatacept
Study Locations (1)
North Carolina
- Duke University Health System - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-07-30 |
| Est. Completion | 2025-09-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03504241
The ClinicalTrials.gov registry entry for NCT03504241 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 268-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (97% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Kidney Transplantation appearing as the primary indexed condition, and to 5 interventions - of which sirolimus is the first listed.
NCT03504241 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03504241 about?
NCT03504241 is a clinical study titled "Tolerance by Engaging Antigen During Cellular Homeostasis". Anti-rejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent rejection of the new organ. Long-term use of these medicines places transplant recipients at higher risk of serious infections and certain types of cancer. The purpose of this s...
What is the current status of trial NCT03504241?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-07-30. Estimated completion is 2025-09-16.
What conditions does trial NCT03504241 study?
This clinical trial studies the following conditions: Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient.
What interventions are being tested in trial NCT03504241?
The interventions under investigation include: sirolimus (DRUG), mycophenolate mofetil (DRUG), Donor-derived Mesenchymal Stromal Cells (BIOLOGICAL), alemtuzumab (DRUG), belatacept (DRUG).
Who is sponsoring clinical trial NCT03504241?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03504241 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD
RECRUITING · Phase 1
-
Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD
RECRUITING · Phase 1
-
CCFZ533X2201 - PoC Study in de Novo Renal Transplantation
COMPLETED · Phase 1
-
Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults
COMPLETED · Phase 1
-
Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.
RECRUITING · Phase 4
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.